Coaching program for women on ribociclib and aromatase inhibitor
Part of Cancer clinical trials.
This study tests whether a coaching program based on personality types helps women with early-stage hormone receptor-positive, HER2-negative breast cancer stick to their treatment plan. Participants must be taking ribociclib (Kisqali) and an aromatase inhibitor, and their cancer must not have spread to other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with invasive breast cancer that is hormone receptor-positive (ER and/or PR positive) and HER2-negative.
- Your doctor has prescribed ribociclib (Kisqali) combined with an aromatase inhibitor (like letrozole) for early-stage breast cancer.
- You are at least 18 years old and willing to sign a consent form.
- Your cancer has not spread to other organs (stage IV) and you have not had a recurrence after surgery.
- You are generally healthy (no serious infections, heart rhythm problems, or allergies to ribociclib or its ingredients like peanuts or soy).
- If you could become pregnant, you must agree to use highly effective birth control and have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps women with early-stage hormone-receptor-positive breast cancer take their oral medication (abemaciclib) consistently and correctly. The goal is to improve how well women stick with this treatment by offering support and education.
This study observes people with early-stage hormone receptor positive, HER2-negative breast cancer who are taking ribociclib (Kisqali) with hormone therapy after surgery. It aims to see how well the treatment works and how safe it is in real life.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
Hear when a new HR+/HER2- Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.